Healiva, a patient-centric company delivering precision medicine for chronic and acute wounds, is acquiring critical manufacturing assets from B.Braun Medical AG Switzerland, an affiliate of German medical and pharmaceutical device company, B. Braun SE. The acquisition includes a qualified cell bank, which is essential for the GMP manufacturing of Healiva’s first cell therapy product, EpiDex, an autologous epidermis derived from the patient’s own hair cells. Financial details have not been discl...